Loading...
Two recently marketed formulations of oral mesalamine (Lialda and Apriso) have been approved for once-daily dosing to maintain remission of ulcerative colitis. The efficacy of these formations when administered as a single dose has been attributed to their delayed-release mechanisms. Clinical trials have shown that an older form of slow-release mesalamine (Pentasa) also is effective when administered once daily.
To test whether another older delayed-release mesalamine formulation (Asacol) is as effective when given once daily versus twice daily, investigators conducted an industry-supported, multicenter, randomized study involving 1023 patients with mild-to-moderate ulcerative colitis. In all patients, clinical remission had been maintained …